Source: ERS Course 2021 - COVID-19: State of the art



Rating:

Share or cite this content

Citations should be made in the following way:
J. Beigel (Baltimore, United States of America). Management of COVID-19: Drugs anti-virals. ERS Course 2021 - COVID-19: State of the art

Member's Comments

No comment yet.

Related content which might interest you: Management of COVID-19: Drugs anti-inflammatories Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Drugs anti-virals Source: Virtual Congress 2020 – Management Year: 2020 Workshop: Antibiotics Source: Research Seminar 2006 - Preventing respiratory sequelae in children diagnosed with cystic fibrosis by newborn screening Year: 2006 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update Source: Eur Respir J 2003; 22: 1 Year: 2003 Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Preventing respiratory diseases: The WHO-ERS Smoking Cessation Training Project Source: International Congress 2019 – The future of respiratory diseases: what prevention can do Year: 2019 Psychiatric Complications in Patients Receiving Treatment for Multi-Drug Resistant Tuberculosis Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Severe Asthma, Current Options and Limitations of Pharmacotherapy Source: Research Seminar 2007 - Severe Asthma Year: 2007 Introduction to The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Source: Eur Respir J 2002; 20: Suppl. 38, 426s Year: 2002 Nature, Magnitude and Risk Factors of Adverse Drug Reactions in Multidrug Resistant TB Patients in Eritrea Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Guideline Adherence and Identifying Cost Effective Medication Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Drugs anti-inflammatories Source: Virtual Congress 2020 – Management Year: 2020 Late Breaking Abstract - SUPRAnav: A Clinical Trial Evaluating the Efficacy and Safety of a New Invention Device Designed for Continuous Supraglottic Aspiration in Mechanically Ventilated Patients. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019 Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 Source: Eur Respir J, 53 (5) 1900164; 10.1183/13993003.00164-2019 Year: 2019 Late Breaking Abstract - Characteristics of Patients Diagnosed with Severe Asthma at UK Specialist Centres: Variation by Ethnicity Source: International Congress 2019 – Bronchiectasis Year: 2019 E-DETECT TB Project: Outreach for Early Tuberculosis Diagnosis Source: ERS webinars 2019 - E-DETECT TB Project: Outreach for Early Tuberculosis Diagnosis Year: 2019 Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs Source: Eur Respir Rev, 30 (162) 210258; 10.1183/16000617.0258-2021 Year: 2021